Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Dirnhofer

Showing results (141-150 of 155) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2015
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)Christoph Mamot, Dirk Klingbiel, Felicitas Hitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)Michael C Heinrich, Grant A McArthur, George D Demetri, et al.
Breast Cancer Research and Treatment|November 30, 2004
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancerGilbert Spizzo, Philip Went, Stephan Dirnhofer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinasesMichael C Heinrich, Heikki Joensuu, George D Demetri, et al.
Blood|November 1, 2014
Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphomaAndre Weilemann, Michael Grau, Tabea Erdmann, et al.
The Journal of Clinical Investigation|February 8, 2019
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasmsSimona Stivala, Tamara Codilupi, Sime Brkic, et al.
Histopathology|May 5, 2021
Burkitt lymphoma with a granulomatous reaction: an M1/Th1-polarised microenvironment is associated with controlled growth and spontaneous regressionMassimo Granai, Stefano Lazzi, Virginia Mancini, et al.
Blood|January 24, 2015
DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic featuresAlberto J Arribas, Andrea Rinaldi, Afua A Mensah, et al.
Oncotarget|October 21, 2017
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibitionGongda Xue, Reto Kohler, Fengyuan Tang, et al.
Nature|August 2, 2019
Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasionAnna M Paczulla, Kathrin Rothfelder, Simon Raffel, et al.
Pageof 16

Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2015
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)Christoph Mamot, Dirk Klingbiel, Felicitas Hitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)Michael C Heinrich, Grant A McArthur, George D Demetri, et al.
Breast Cancer Research and Treatment|November 30, 2004
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancerGilbert Spizzo, Philip Went, Stephan Dirnhofer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinasesMichael C Heinrich, Heikki Joensuu, George D Demetri, et al.
Blood|November 1, 2014
Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphomaAndre Weilemann, Michael Grau, Tabea Erdmann, et al.
The Journal of Clinical Investigation|February 8, 2019
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasmsSimona Stivala, Tamara Codilupi, Sime Brkic, et al.
Histopathology|May 5, 2021
Burkitt lymphoma with a granulomatous reaction: an M1/Th1-polarised microenvironment is associated with controlled growth and spontaneous regressionMassimo Granai, Stefano Lazzi, Virginia Mancini, et al.
Blood|January 24, 2015
DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic featuresAlberto J Arribas, Andrea Rinaldi, Afua A Mensah, et al.
Oncotarget|October 21, 2017
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibitionGongda Xue, Reto Kohler, Fengyuan Tang, et al.
Nature|August 2, 2019
Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasionAnna M Paczulla, Kathrin Rothfelder, Simon Raffel, et al.
Pageof 16